Search Result

Results for "

SHP2 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	SHP2 (85) Akt (2) Apoptosis (12) Atg8/LC3 (1) ATTECs (1) AUTACs (1) Autophagy (2) Bacterial (2) Casein Kinase (2) CDK (1) Endogenous Metabolite (2) ERK (5) FGFR (1) Fluorescent Dye (1) HDAC (1) Isotope-Labeled Compounds (1) JAK (1) MAPKAPK2 (MK2) (1) MEK (1) p38 MAPK (2) Phosphatase (39) PI3K (1) PROTACs (1) Reactive Oxygen Species (ROS) (2) Reference Standards (3) SHP1 (9) STAT (1)
By Research Areas:	Cancer (80) Cardiovascular Disease (2) Inflammation/Immunology (5) Metabolic Disease (5) Neurological Disease (2)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: SHP2

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145159

SHP2 protein degrader-1	SHP2 PROTACs Phosphatase Apoptosis	Cancer
SHP2 protein degrader-1 is a potent allosteric inhibitor of *SHP2. SHP2* protein degrader-1 induces SHP2 degradation and cell apoptosis. SHP2 protein degrader-1 has the potential for researching SHP2 related diseases .

HY-121879

SHP836 1 Publications Verification	SHP2 Phosphatase	Cancer
SHP836 is a *SHP2* allosteric inhibitor, with an IC₅₀ of 12 μM for the full length SHP2 .

HY-115925

SHP2-IN-9	SHP2 Phosphatase	Cancer
SHP2-IN-9 is a specific *SHP2* inhibitor (IC₅₀ =1.174 μM) with enhanced blood–brain barrier penetration. SHP2-IN-9 shows 85-fold more selective for SHP2 than SHP1. SHP2-IN-9 inhibits SHP2-mediated cell signal transduction and cancer cell proliferation, and inhibits the growth of cervix cancer tumors and glioblastoma growth in vivo .

HY-125257

SHP2 inhibitor LY6 LY6	SHP2 Phosphatase	Cancer
SHP2 inhibitor LY6 (LY6) is potent and selective inhibitor of *SHP2, with an IC₅₀* of 9.8 µM. SHP2 inhibitor LY6 can inhibits SHP2-mediated cell signaling and proliferation .

HY-157888

SHP2-IN-26	SHP2 Phosphatase	Cancer
SHP2-IN-26 (Compound 4b) is a highly selective *SHP2* allosteric inhibitor with a IC₅₀ value of 3.2 nM. SHP2-IN-26 inhibits the phosphorylation of ERK and AKT in NCI-H358 cells. SHP2-IN-26 has antitumor activity .

HY-169111

SHP2-IN-32	SHP2	Cancer
SHP2-IN-32 (compound C6) is an orally active, allosteric *SHP2* inhibitor with an IC₅₀ value of 0.13 nM. SHP2-IN-32 exhibits antitumor activity .

HY-162755

SHP2-IN-30	SHP2 Apoptosis	Cancer
SHP2-IN-30 (compound 14i) is an allosteric *SHP2* inhibitor with an IC₅₀ of 104 nM. SHP2-IN-30 shows low inhibitory effect on SHP2-PTP. SHP2-IN-30 induces cell apoptosis and arrests the cell cycle at the G0/G1 phase .

HY-164427

SHP2-IN-31	SHP2 ERK	Cancer
SHP2-IN-31 is a *SHP2* inhibitor, with IC₅₀s of 13 nM (Wild-type SHP2), >10000 nM (SHP1), >10000 nM (SHP2 E76K) . SHP2-IN-31 inhibits pERK in a panel of tumor cells. SHP2-IN-31 inhibits tumor growth in RTK/KRAS-driven xenograft models .

HY-130631

SHP2-IN-5	SHP2	Cancer
SHP2-IN-5 (compound 1) is an inhibitor of SHP2 (IC₅₀: 97 nM). SHP2 is a non-receptor protein tyrosine phosphatase associated with cell growth and proliferation. SHP2-IN-5 has the potential to inhibit cancer and SHP2-related human diseases .

HY-144396

SHP2-IN-8	SHP2 Phosphatase Akt Apoptosis	Cancer
SHP2-IN-8 is a highly potent, selective, and cellularly active allosteric *SHP2* inhibitor with IC₅₀ value of 23 nM and K_i of 22 nM. SHP2-IN-8 is reversible and noncompetitive. SHP2-IN-8 causes a significant thermal shift with the ΔTm of 7.01 ℃. SHP2-IN-8 induces the apoptosis and inhibits the phosphorylation of AKT in Hela cells .

HY-155276

SHP2-IN-20	SHP2	Cancer
SHP2-IN-20 (compound 193) is a *SHP2* inhibitor with an IC₅₀ value of 3 nM. SHP2-IN-20 can be used for glioblastoma research .

HY-155272

SHP2-IN-16	SHP2	Cancer
SHP2-IN-16 (compound 222) is a *SHP2* inhibitor with an IC₅₀ value of 1 nM. SHP2-IN-16 can be used for glioblastoma research .

HY-155273

SHP2-IN-17	SHP2	Cancer
SHP2-IN-17 (compound 192) is a *SHP2* inhibitor with an IC₅₀ value of 2 nM. SHP2-IN-17 can be used for glioblastoma research .

HY-162233

SHP2-IN-25	SHP2 Phosphatase	Cancer
SHP2-IN-25 (Compound 6) is a *SHP2* allosteric inhibitor, with an IC₅₀ of 225 nM. SHP2-IN-25 can be used for the research of cancer .

HY-155275

SHP2-IN-19	SHP2	Cancer
SHP2-IN-19 (compound 183) is a *SHP2* inhibitor with an IC₅₀ value of 3 nM. SHP2-IN-19 can be used for glioblastoma research .

HY-155277

SHP2-IN-21	SHP2	Cancer
SHP2-IN-21 (compound 208) is a *SHP2* inhibitor with an IC₅₀ value of 3 nM. SHP2-IN-21 can be used for glioblastoma research .

HY-155274

SHP2-IN-18	SHP2	Cancer
SHP2-IN-18 (compound 183) is a *SHP2* inhibitor with an IC₅₀ value of 3 nM. SHP2-IN-18 can be used for glioblastoma research .

HY-171959

SHP2-IN-39	SHP2	Cancer
SHP2-IN-39 (Example 63) is an inhibitor of *SHP2* with an IC₅₀ of 0.007 μM. SHP2-IN-39 can be used in the research of cancer .

HY-162476

SHP2-IN-28	SHP2	Cancer
SHP2-IN-28 (Compound 7188-0011) is an inhibitor of *SHP2* (IC₅₀=54.31 μM). SHP2-IN-28 exerts its inhibitory effect by binding to the variable site of SHP2 with high selectivity .

HY-149241

SHP2-IN-13	SHP2	Cancer
SHP2-IN-13 is a highly selective and orally active SHP2 “tunnel site” allosteric inhibitor with an IC50 of 83.0 nM. SHP2-IN-13 has the potential for cancers bearing RTK oncogenic drivers and SHP2-related diseases research.

HY-171960

SHP2-IN-40	SHP2	Cancer
SHP2-IN-40 (Compound 25) is an inhibitor of *SHP2* with an AC₅₀ of 0.0107 μM. SHP2-IN-40 can be used in the research of cancer .

HY-157318

PB17-026-01	SHP2	Cancer
PB17-026-01 is a potent SHP2 allosteric inhibitor and shows the highest inhibitory activity with an IC₅₀ value of 38.9?nM. PB17-026-01 can be used for the research of tumor .

HY-149607

SHP2-IN-22	SHP2	Cancer
SHP2-IN-22 is *SHP2* allosteric inhibitor with an IC₅₀ value of 17.7 nM. SHP2-IN-22 inhibits the proliferation, migration, and invasion of MIA PaCa-2 pancreatic cancer cells. SHP2-IN-22 can be used for Kirsten rat sarcoma viral oncogene (KRAS) mutant cancer research .

HY-114460

SHP2-IN-1	SHP2 Phosphatase	Others
SHP2-IN-1 (compound 13) is an allergic inhibitor of SHP2 (PTPN11), with an IC₅₀ of 3 nM.

HY-169918

SHP2-IN-34	SHP2	Cancer
SHP2-IN-34 (compound A8) is a phenyl urea *SHP2* inhibitor with anti-cancer activity. SHP2-IN-34 significantly suppresses tumor growth in CT26 mouse model .

HY-174239

SHP2-IN-41	SHP2	Cancer
SHP2-IN-41 (Compound 4) is a *SHP2* inhibitor with an IC₅₀ of less than 0.1 μM. SHP2-IN-41 has an IC₅₀ against KYSE-520 cells also less than 0.1 μM. SHP2-IN-41 can be used in the study of cancer .

HY-174322

SHP2-IN-38	SHP2 ERK Fluorescent Dye	Cancer
SHP2-IN-38 is a novel green-fluorescent *SHP2* inhibitor with IC₅₀ values of 2.89 μM (SHP2), 8.73 μM (SHP1), 11.08 μM (PTP1B), 33.07 μM (TCPTP). SHP2-IN-38 blocks the SHP2-mediated ERK signaling pathway and inhibits MV4-11 cells proliferation in vitro with IC₅₀ of 7.90 μM. SHP2-IN-38 has an excitation wavelength of 360 nm, with a maximum emission wavelength of 550 nm in DMSO and 540 nm in DMF. SHP2-IN-38 shows green fluorescence imaging in HeLa cells and zebrafish.

HY-149759

SHP2-IN-23	SHP2 ERK	Cancer
SHP2-IN-23 (compound 30) is an orally active *SHP2* inhibitor (IC₅₀=38 nM) with excellent in vivo efficacy and pharmacokinetic profiles. SHP2-IN-23 inhibits ERK phosphorylation with IC₅₀=5 nM .

HY-151464

SHP2/HDAC-IN-1	SHP2 Phosphatase HDAC	Inflammation/Immunology Cancer
SHP2/HDAC-IN-1 is a dual allosteric *SHP2/HDAC* inhibitor with IC₅₀ values of 20.4 nM (SHP2) and 25.3 nM (HDAC1) respectively. SHP2/HDAC-IN-1 triggers efficient antitumor immunity by activating T cells, enhancing the antigen presentation function and promoting cytokine secretion. SHP2/HDAC-IN-1 can be used in the research of cancer immunoresearch .

HY-172454

SHP2-IN-36	SHP2	Cancer
SHP2-IN-36 (Compound B8) is an allosteric inhibitor of *SHP2, with an IC₅₀* value of 9.0 nM. In addition, its IC₅₀ for p-ERK is 40 nM. SHP2-IN-36 also exhibited significant antitumor activity in the KYSE520 xenograft mouse model. SHP2-IN-36 can be used for research in the field of anti-tumor .

HY-114453

SHP389	SHP2 Phosphatase	Others
SHP389 is an allosteric *SHP2* inhibitor, with an IC₅₀ of 36 nM for both SHP2 and p-ERK .

HY-125259

SHP504	SHP2 Phosphatase	Cancer
SHP504 is a SHP2 phosphatase inhibitor, with an IC₅₀ of 21 μM for SHP2 ^1–525 .

HY-N12915

SHP2-IN-29	SHP2 Phosphatase	Metabolic Disease Cancer
SHP2-IN-29 (Compound 3) is a potent *SHP2* inhibitor with an IC₅₀ value of 0.18 μM. SHP2-IN-29 also has inhibitory activity against PTP1B and TCPTP, with IC₅₀ values of 4.27 and 4.74 μM, respectively.

HY-157535

SHP2-IN-24	SHP2	Cancer
SHP2-IN-24 (compound 111675) is a potent *SHP2* inhibitor with an IC₅₀ value of 0.878 µM and a K_i value of 0.118 µM .

HY-170877

SHP2-IN-35	SHP2 PI3K Akt Autophagy	Cancer
SHP2-IN-35 (Compound 3f) is the inhibitor for *SHP2. SHP2-IN-35 exhibits antiproliferative activity in cancer cells RKO, SW480 and CT26 with IC₅₀* of 5.72 μM, 3.71 μM and 1.42 μM, respectively. SHP2-IN-35 inhibits the PI3K-Akt signaling pathway, regulates the cell cycle associated gene expressions, and induces mitochondrial-related autophagy. SHP2-IN-35 inhibits the expression of certain cytokines and chemokines in the tumor microenvironment (TME), thereby regulating the tumor progression .

HY-153699

SHP2-IN-14	SHP2	Cancer
SHP2-IN-14 (compound 27) is an orally active and potent *SHP2* allosteric inhibitor (IC₅₀=7 nM) with anti-tumor activity. SHP2-IN-14 inhibits tumor progression in NCI-H358 tumor bearing mice, exhibits good pharmacokinetic characteristics and safty .

HY-168715

SHP2-IN-33	SHP2 Apoptosis MAPKAPK2 (MK2)	Cancer
SHP2-IN-33 (Compound D13) is an allosteric inhibitor of *SHP2* with an IC₅₀ of 1.2 μM. In cellular studies, SHP2-IN-33 demonstrates antiproliferative activity with an IC₅₀ of 38 μM against Huh7 cells by arresting the G0/G1 cell cycle, promoting apoptosis (Apoptosis), and suppressing the MAPK signaling pathway. In an in vivo Huh7 xenograft mouse model, SHP2-IN-33 exhibits significant antitumor activity and favorable pharmacokinetics, including 54% oral bioavailability and a half-life of 10.57 hours. SHP2-IN-33 is a promising compound for studying tumor diseases associated with *SHP2* .

HY-100388

SHP099 Maximum Cited Publications 69 Publications Verification	SHP2 Phosphatase	Cancer
SHP099 is an allosteric *SHP2* inhibitor, with IC₅₀s of 0.690, 1.241, 0.416, 1.968, 2.896 μM for SHP2, SHP2 ^D61Y, SHP2E69K, SHP2 ^A72V, SHP2 ^E76K. SHP099 inhibits cancer cell growth, such as MV4-11 and TF-1 cell (IC₅₀: 0.32 and 1.73 μM). SHP099 inhibits RAS-ERK signaling and inhibits tumor growth .

HY-172911

SHP2-IN-37	SHP2	Cancer
SHP2-IN-37 (compound C5) is a potent and selective *SHP2* allosteric inhibitor with an IC₅₀ of 0.023 μM. SHP2-IN-37 exhibits antiproliferative effect on KYSE-520 and MV-411 cells with IC₅₀s of 6.97 and 0.67 μM, respectively

HY-141524

RMC-3943	SHP2 Phosphatase	Cancer
RMC-3943 is an allosteric *SHP2* inhibitor (inhibition of full-length SHP2 in biochemical assay, IC₅₀ = 2.19 nM) .

HY-131132

JAB-3068 SHP2-IN-6	SHP2 Phosphatase	Cancer
JAB-3068 (SHP2-IN-6) is a potent *SHP2* inhibitor, extracted from patent WO2017211303A1, compound 7, has an IC₅₀ of 25.8 nM .

HY-150609

SHP2/CDK4-IN-1	SHP2 Phosphatase CDK	Cancer
SHP2/CDK4-IN-1 (compound 10) is an orally active and potent *SHP2* and CDK4 dual inhibitor, with IC₅₀ values of 4.3 and 18.2 nM, respectively. SHP2/CDK4-IN-1 effectively induces G0/G1 arrest to prevent the proliferation of TNBC cell lines. SHP2/CDK4-IN-1 shows significant antitumor efficacy in the EMT6 syngeneic mouse model. SHP2/CDK4-IN-1 can be used for triple-negative breast cancer (TNBC) research .

HY-173560

SHP2 ATTEC degrader-1	ATTECs SHP2 Apoptosis	Cancer
SHP2 ATTEC degrader-1 is a *SHP2* ATTEC degrader. SHP2 ATTEC degrader-1 has degradation rate of 83.31 at 1.0 μM for 24 h in the PANC-1 cell line. SHP2 ATTEC degrader-1 inhibits cell growth in vivo and in vitro. SHP2 ATTEC degrader-1 induces apoptosis and increases the expression of the epithelial marker ( E-cadherin)， and reduces the expression of interstitial markers (such as N-cadherin, Vimentin) (Pink: LC3 ligand (HY-174085); Black :linker HY-140468; Blue: SHP2 ligand (HY-174084) .

HY-125108

PHPS1 sodium 3 Publications Verification	SHP2 SHP1 Phosphatase	Cardiovascular Disease Cancer
PHPS1 sodium is a potent and selective *Shp2* inhibitor with K_is of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively .

HY-112368

PHPS1 3 Publications Verification	SHP2 SHP1 Phosphatase	Cardiovascular Disease Cancer
PHPS1 is a potent and selective *Shp2* inhibitor with K_is of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively .

HY-175204

SHP2 protein degrader-3	AUTACs SHP2 Apoptosis Autophagy Atg8/LC3	Cancer
SHP2 protein degrader-3 is a *SHP2* AUTAC degrader. SHP2 protein degrader-3 shows dose-dependent *SHP2* degradation ability (DC₅₀ = 3.22 μM) and anti-tumor activity (IC₅₀ = 5.59 μM) in HeLa cells. SHP2 protein degrader-3 induces degradation through the LC3-mediated autophagy pathway, which can be inhibited by lysosome inhibitors. SHP2 protein degrader-3 induces apoptosis in various cancer cells (HeLa cells, HepG2 cells, LoVo cells, Huh-7 cells) (SHP2 Ligand : (HY-100388); LC3 Ligand: (HY-10542); Linker : (HY-128834)) .

HY-131132A

JAB-3068 hydrochloride SHP2-IN-6 hydrochloride	SHP2 Phosphatase	Cancer
JAB-3068 (SHP2-IN-6) hydrochloride is a potent *SHP2* inhibitor with an IC₅₀ of 25.8 nM. JAB-3068 hydrochloride is extracted from patent WO2017211303A1, compound 7 .

HY-125260

SHP844	SHP2	Cancer
SHP844 is a SHP2 inhibitor with the IC₅₀ of 18.9 µM. SHP2 is a protein tyrosine phosphatase (PTP) that regulates tyrosine phosphorylation levels and is involved in cell proliferation, differentiation and survival .

HY-173571

TK-685	SHP2 Apoptosis	Cancer
TK-685 is an orally active, selective, and allosteric *SHP2* inhibitor with an IC₅₀ of 2.1 nM. TK-685 inhibits esophageal cancer cell proliferation and induced apoptosis by targeting *SHP2*-mediated AKT and ERK signaling pathways .

HY-162355

SHP2-IN-27	SHP2	Cancer
SHP2-IN-27 (compound 28) is an allosteric inhibitor of tyrosine phosphatase SH2 .

Cat. No.	Product Name	Target	Research Area

HY-P3444

CD31 PECAM-1	SHP2 Bacterial	Metabolic Disease Inflammation/Immunology
CD31 (PECAM-1) is platelet endothelial cell adhesion molecule-1, serves as the endothelial cell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 peptide is able to sustain phosphorylation of the CD31 ITIM₆₈₆ and of *SHP2* and to inhibit TCR-induced T-cell activation ^- .

HY-P3444A

CD31 TFA PECAM-1 TFA	SHP2 Bacterial	Metabolic Disease Inflammation/Immunology
CD31 (PECAM-1) TFA is platelet endothelial cell adhesion molecule-1, serves as the endothelial cell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 TFA is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 TFA peptide is able to sustain phosphorylation of the CD31 ITIM₆₈₆ and of *SHP2* and to inhibit TCR-induced T-cell activation ^- .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0183

Ellagic acid 15+ Cited Publications	Structural Classification Neurological Disease Classification of Application Fields Anti-aging Source classification Plants Endogenous metabolite Microorganisms other families Phenols Polyphenols Disease Research Fields Cancer	Casein Kinase Reactive Oxygen Species (ROS) Endogenous Metabolite SHP2
Ellagic acid is a natural antioxidant, and acts as a potent and ATP-competitive inhibitor of CK2 and *SHP2, with an IC₅₀* of 40 nM and a K_i of 20 nM.

HY-N12915

SHP2-IN-29	Structural Classification Monophenols Microorganisms Source classification Phenols	SHP2 Phosphatase
SHP2-IN-29 (Compound 3) is a potent *SHP2* inhibitor with an IC₅₀ value of 0.18 μM. SHP2-IN-29 also has inhibitory activity against PTP1B and TCPTP, with IC₅₀ values of 4.27 and 4.74 μM, respectively.

HY-N10079

Suchilactone Jatrophan	Structural Classification Polygala chinensis Linnaeus Source classification Polygalaceae Lignans Phenylpropanoids Plants	SHP2
Suchilactone (Jatrophan) is a lignan extracted from Monsonia angustifolia E.Mey. Suchilactone binds to *SHP2* and inhibits SHP2 activation, thereby inhibiting ERK-mediated cell proliferation. Suchilactone can be ued in acute myeloid leukaemia (AML) .

HY-B0183R

Ellagic acid (Standard)	Structural Classification Microorganisms other families Source classification Phenols Polyphenols Plants Endogenous metabolite	Reference Standards Casein Kinase Reactive Oxygen Species (ROS) Endogenous Metabolite SHP2
Ellagic acid (Standard) is the analytical standard of Ellagic acid. This product is intended for research and analytical applications. Ellagic acid is a natural antioxidant, and acts as a potent and ATP-competitive inhibitor of CK2 and SHP2, with an IC50 of 40 nM and a Ki of 20 nM.

HY-N12177

Cryptosporioptide A	Structural Classification Flavonoids Microorganisms Source classification Other Flavonoids	Phosphatase SHP1
Cryptosporioptide A (Compound 3) is a pigment protein tyrosine phosphatase inhibitor derived from the insect-parasitic fungus Cordyceps gracilioides. Cryptosporioptide A inhibits PTP1B, SHP2, CDC25B, LAR and SHP1 enzymes with IC₅₀ of 7.3, 5.7, 7.6, >50, 4.9 μg/mL, respectively .

Cat. No.	Product Name	Chemical Structure

HY-B0183S

Ellagic acid-13C12
Ellagic acid- ¹³C₁₂ is ¹³ C-labeled Ellagic acid (HY-B0183). Ellagic acid is a natural antioxidant and acts as a potent and ATP-competitive inhibitor of CK2 and *SHP2, with an IC₅₀* of 40 nM and a K_i of 20 nM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

SHP2 inhibitor

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products